Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial
Authors' conclusion
In patients with varying degrees of kidney function, canagliflozin reduced cardiovascular and kidney outcomes, regardless of age, with no additional safety concerns identified in older patients.
Study context
- Population
- Participants with T2D in the CANVAS Program and CREDENCE trial, with varying degrees of kidney function; older participants had more atherosclerotic CVD and HF, longer DM duration and lower mean eGFR2 trials pooled · CREDENCE trial 4,401
- Participants
- 14,543 participants
- Comparison
- Canagliflozin by baseline age category
- <65 yearsn = 7,927
- 65 to <75 yearsn = 5,281
- ≥75 yearsn = 1,335
- Outcome
- Effects of canagliflozin on CV and kidney outcomes (incl. MACE, CKD progression) by age
Methodological detailsindividual participant data, subgroup analysis by baseline age, Cox proportional hazards models and Fine and Gray competing risk analysis
- Individual participant data
- Subgroup analysis by baseline age
- Cox proportional hazards models and Fine and Gray competing risk analysis
Pooled result
As reported in the abstract
- Reductions in CV and kidney outcomes with canagliflozin consistent across age categories
- all p trend >0.10
- Effects on CV death attenuated with older age
- p trend = 0.02
- Effects on all-cause death attenuated with older age
- p trend = 0.03
Safety
Safety outcomes (acute kidney injury, volume depletion, UTI, hypoglycaemia) by age
- Effects of canagliflozin on safety outcomes not modified by age
- all p trend >0.10
- Incidence of adverse events increased with age
Original publication
Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab. Published 9 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →